When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Adalimumab - Wikipedia

   en.wikipedia.org/wiki/Adalimumab

   Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

3. AbbVie's tight grip on Humira market raises concerns about ...

   www.aol.com/news/abbvies-tight-grip-humira...

   AbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market ...

4. TNF inhibitor - Wikipedia

   en.wikipedia.org/wiki/TNF_inhibitor

   A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response.TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their ...

5. Management of Crohn's disease - Wikipedia

   en.wikipedia.org/wiki/Management_of_Crohn's_disease

   Management of Crohn's disease involves first treating the acute symptoms of the disease, then maintaining remission. Since Crohn's disease is an immune system condition , it cannot be cured by medication or surgery.

6. Cigna to remove AbbVie's Humira from some drug ... - AOL

   www.aol.com/news/cigna-remove-abbvies-humira...

   Humira was once the world's biggest selling prescription medicine with peak sales of $21.2 billion in 2022. Express Scripts and UnitedHealth Group's Optum Rx - two of the largest PBMs - chose to ...

7. Can AbbVie's (ABBV) New Drugs Make up for Lost Humira ... - AOL

   www.aol.com/news/abbvies-abbv-drugs-lost-humira...

   AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.